CME

Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T ce...

Faculty: Joshua Richter, MD Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are...

Faculty: Joshua Richter, MD Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a clas...

Faculty: Joshua Richter, MD Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are...

Faculty: Joshua Richter, MD Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a clas...

Faculty: Sagar Lonial, MD, FACP Faculty: Noopur Raje, MD Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a...

Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhan...

Faculty: Sagar Lonial, MD, FACP Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhan...

Host: Brian P. McDonough, MD, FAAFP Guest: Silvio Inzucchi, MD Guest: Darren McGuire, MD, MHSc Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individual...

Host: Maria Fleseriu, MD, FACE Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and healthcare systems. Patients often experience delays in diagnosis, averaging 4 to 6 years, which exacerbates disease progression and leads to irreversible comorbidities. Do you know how to effectively treat acromegaly to increase...

Faculty: Kevin Alexander, MD This brief clinical discussion examines findings presented at the ESC Heart Failure 2025 meeting in Belgrade, Serbia, on the impact of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis highlights a reduction in atrial fibrillation events and an improvement in cardiovascular outcomes among patients treated with acoramidis, including those with b...

Host: Aristides Maniatis, MD Guest: Kari Hosack Guest: Meagan Broeckert Guest: Sam Watson Join Dr. Aristides Maniatis for this Patient-Clinician Connection, a case-based activity that explores the full spectrum of care in Growth Hormone Deficiency. Through real patient and caregiver dialogues, this program teaches clinicians how to identify early signs of GHD, make accurate diagnoses, navigate ped...

Guest: Heather Wakelee, MD, FASCO Perioperative immunotherapy has evolved into a novel therapeutic strategy for early-stage, resectable NSCLC, maximizing the efficacy of immunotherapy when the primary tumor is still present with a high neoantigen burden. Perioperative immunotherapy also allows the use of preoperative pathology as a guide for postoperative care and offers a pathway to potential sur...

Guest: Hussein Tawbi, MD, PhD Guest: Paolo A. Ascierto, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvan...

Guest: Sapna Patel, MD Guest: John M. Kirkwood, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuv...

Guest: Hussein Tawbi, MD, PhD Guest: Sapna Patel, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adj...

Guest: Hussein Tawbi, MD, PhD Guest: Sapna Patel, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adj...

Guest: Paolo A. Ascierto, MD Guest: Hussein Tawbi, MD, PhD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvan...

Guest: Paolo A. Ascierto, MD Guest: Hussein Tawbi, MD, PhD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvan...

Guest: Paolo A. Ascierto, MD Guest: Hussein Tawbi, MD, PhD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvan...

Guest: Paolo A. Ascierto, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic se...

Guest: John M. Kirkwood, MD Guest: Sapna Patel, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuv...

Guest: John M. Kirkwood, MD Guest: Sapna Patel, MD This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuv...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...

Host: Stephen Liu, MD Guest: Joshua K. Sabari, MD Guest: Susan Scott, MD The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microle...